ANDAORALTABLET
Approved
Dec 2018
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GRISEOFULVIN, ULTRAMICROSIZE (ultramicrosize griseofulvin) by Novartis. Approved for tubulin inhibiting agent [epc]. First approved in 2018.
Drug data last refreshed 3d ago
Mechanism of Action
Pharmacologic Class:
Tubulin Inhibiting Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Novartis
BASEL, Switzerland
Worked on GRISEOFULVIN, ULTRAMICROSIZE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.